4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage company specializing in genetic medicines for large market diseases, has announced its participation in two major investor conferences in March 2025.
The company will engage in fireside chats at Leerink's Global Biopharma Conference on Tuesday, March 11, 2025, at 10:00 a.m. ET, and at the Barclays Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET. Management team members will be available for one-on-one meetings during both events.
Webcasts of both presentations will be accessible through the company's website, with archived versions remaining available for up to one year in the 'Investors' section at ir.4dmoleculartherapeutics.com/events.
4D Molecular Therapeutics (Nasdaq: FDMT), un'azienda in fase clinica specializzata in medicinali genetici per malattie di grande mercato, ha annunciato la sua partecipazione a due importanti conferenze per investitori a marzo 2025.
L'azienda parteciperà a discussioni informali durante la Global Biopharma Conference di Leerink martedì 11 marzo 2025, alle 10:00 ET, e alla Global Healthcare Conference di Barclays mercoledì 12 marzo 2025, alle 10:00 ET. I membri del team di gestione saranno disponibili per incontri individuali durante entrambi gli eventi.
I webcast di entrambe le presentazioni saranno accessibili attraverso il sito web dell'azienda, con versioni archiviate disponibili per un massimo di un anno nella sezione 'Investitori' su ir.4dmoleculartherapeutics.com/events.
4D Molecular Therapeutics (Nasdaq: FDMT), una empresa en etapa clínica especializada en medicamentos genéticos para enfermedades de gran mercado, ha anunciado su participación en dos importantes conferencias de inversores en marzo de 2025.
La empresa participará en charlas informales en la Global Biopharma Conference de Leerink el martes 11 de marzo de 2025, a las 10:00 a.m. ET, y en la Global Healthcare Conference de Barclays el miércoles 12 de marzo de 2025, a las 10:00 a.m. ET. Los miembros del equipo de gestión estarán disponibles para reuniones uno a uno durante ambos eventos.
Las transmisiones en vivo de ambas presentaciones estarán accesibles a través del sitio web de la empresa, con versiones archivadas disponibles por hasta un año en la sección 'Inversores' en ir.4dmoleculartherapeutics.com/events.
4D Molecular Therapeutics (Nasdaq: FDMT), 대규모 시장 질병을 위한 유전자 의약품을 전문으로 하는 임상 단계 회사가 2025년 3월 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 11일 화요일 오전 10시 ET에 Leerink의 글로벌 바이오파마 회의와 2025년 3월 12일 수요일 오전 10시 ET에 Barclays 글로벌 헬스케어 회의에서 화로 대화에 참여할 예정입니다. 경영진 팀원들은 두 행사 동안 1:1 회의를 위해 대기할 것입니다.
두 발표의 웹캐스트는 회사 웹사이트를 통해 액세스할 수 있으며, 아카이브 버전은 ir.4dmoleculartherapeutics.com/events의 '투자자' 섹션에서 최대 1년 동안 이용 가능합니다.
4D Molecular Therapeutics (Nasdaq: FDMT), une entreprise en phase clinique spécialisée dans les médicaments génétiques pour les maladies à fort potentiel de marché, a annoncé sa participation à deux grandes conférences pour investisseurs en mars 2025.
L'entreprise participera à des discussions informelles lors de la Global Biopharma Conference de Leerink le mardi 11 mars 2025 à 10h00 ET, et à la Global Healthcare Conference de Barclays le mercredi 12 mars 2025 à 10h00 ET. Les membres de l'équipe de direction seront disponibles pour des réunions individuelles lors des deux événements.
Les webcasts des deux présentations seront accessibles via le site web de l'entreprise, avec des versions archivées disponibles pendant un an dans la section 'Investisseurs' sur ir.4dmoleculartherapeutics.com/events.
4D Molecular Therapeutics (Nasdaq: FDMT), ein klinisches Unternehmen, das sich auf genetische Medikamente für große Märkte spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 angekündigt.
Das Unternehmen wird am Dienstag, den 11. März 2025, um 10:00 Uhr ET an informellen Gesprächen auf der Global Biopharma Conference von Leerink und am Mittwoch, den 12. März 2025, um 10:00 Uhr ET an der Global Healthcare Conference von Barclays teilnehmen. Mitglieder des Managementteams stehen während beider Veranstaltungen für persönliche Gespräche zur Verfügung.
Die Webcasts beider Präsentationen werden über die Unternehmenswebsite zugänglich sein, wobei archivierte Versionen bis zu einem Jahr in der Rubrik 'Investoren' unter ir.4dmoleculartherapeutics.com/events verfügbar bleiben.
- None.
- None.
EMERYVILLE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings.
Leerink's Global Biopharma Conference 2025
Presentation Date: Tuesday, March 11, 2025
Presentation Time: 10:00 a.m. ET
Webcast Link: Webcast
Barclays Global Healthcare Conference 2025
Presentation Date: Wednesday, March 12, 2025
Presentation Time: 10:00 a.m. ET
Webcast Link: Webcast
Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When will 4DMT (FDMT) present at Leerink's Global Biopharma Conference 2025?
What is the schedule for FDMT's presentation at the Barclays Global Healthcare Conference 2025?
How long will the webcasts of FDMT's March 2025 investor conferences be available?
Where can investors access FDMT's March 2025 conference presentations?
Will FDMT management be available for individual meetings during the March 2025 conferences?
